Abstract
22q11.2 Deletion syndrome (22q11DS) is the most common known recurrent copy-number variant disorder. It is also the most common known genetic risk factor for schizophrenia. The greater homogeneity of subjects with schizophrenia in 22q11DS compared with schizophrenia in the wider non-deleted population may help to identify much needed information on neuroanatomical substrates, and neurochemical and neurofunctional mechanisms that may modulate the risk for schizophrenia. Identification of the underlying pathophysiology creates opportunities for developing genotypespecific, biology-based and targeted treatments to prevent, delay or minimize the severity of schizophrenia in both 22q11DS and the wider non-deleted population. This article reviews neuroimaging studies that focused on brain structure and function in this high-risk population, with particular attention to schizophrenia research. We also discuss the evidence on the role of candidate genes within the 22q11.2 region, with particular reference to catechol-O-methyl transferase (COMT) and proline dehydrogenase (PRODH).
Keywords: 22q11.2 Deletion syndrome, velocardiofacial syndrome, schizophrenia, psychosis, neuroimaging.
Current Topics in Medicinal Chemistry
Title:Neuroimaging Correlates of 22q11.2 Deletion Syndrome: Implications for Schizophrenia Research
Volume: 12 Issue: 21
Author(s): E. Boot and T.A.M.J. van Amelsvoort
Affiliation:
Keywords: 22q11.2 Deletion syndrome, velocardiofacial syndrome, schizophrenia, psychosis, neuroimaging.
Abstract: 22q11.2 Deletion syndrome (22q11DS) is the most common known recurrent copy-number variant disorder. It is also the most common known genetic risk factor for schizophrenia. The greater homogeneity of subjects with schizophrenia in 22q11DS compared with schizophrenia in the wider non-deleted population may help to identify much needed information on neuroanatomical substrates, and neurochemical and neurofunctional mechanisms that may modulate the risk for schizophrenia. Identification of the underlying pathophysiology creates opportunities for developing genotypespecific, biology-based and targeted treatments to prevent, delay or minimize the severity of schizophrenia in both 22q11DS and the wider non-deleted population. This article reviews neuroimaging studies that focused on brain structure and function in this high-risk population, with particular attention to schizophrenia research. We also discuss the evidence on the role of candidate genes within the 22q11.2 region, with particular reference to catechol-O-methyl transferase (COMT) and proline dehydrogenase (PRODH).
Export Options
About this article
Cite this article as:
Boot E. and van Amelsvoort T.A.M.J., Neuroimaging Correlates of 22q11.2 Deletion Syndrome: Implications for Schizophrenia Research, Current Topics in Medicinal Chemistry 2012; 12 (21) . https://dx.doi.org/10.2174/1568026611212210003
DOI https://dx.doi.org/10.2174/1568026611212210003 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Is Elevated Norepinephrine an Etiological Factor in Some Cases of Alzheimers Disease?
Current Alzheimer Research New Devices for Treating Acute Ischemic Stroke
Recent Patents on CNS Drug Discovery (Discontinued) Amiodarone Hepatotoxicity
Current Vascular Pharmacology Antibacterial and Antioxidant Property of Streptomyces cinnamonensis VITNS1 Isolated from Serkadu Region, Vellore, Tamil Nadu, India
Anti-Infective Agents Potential Use of Dietary Natural Products, Especially Polyphenols, for Improving Type-1 Allergic Symptoms
Current Pharmaceutical Design Psoriasis and Vascular Risk : An Update
Current Pharmaceutical Design Peroxisome Proliferator-Activated Receptor γ Agonists as Insulin Sensitizers: From the Discovery to Recent Progress
Current Topics in Medicinal Chemistry Mechanisms Involved in Metformin Action in the Treatment of Polycystic Ovary Syndrome
Current Pharmaceutical Design Nuclear Imaging of Post-infarction Inflammation in Ischemic Cardiac Diseases - New Radiotracers for Potential Clinical Applications
Current Radiopharmaceuticals Innate Immunity, Toll-Like Receptors, and Diabetes
Current Immunology Reviews (Discontinued) Effects of Simvastatin on the Metabolism of Fatty Acids in Combined Secondary Prevention of Coronary Heart Disease: Dosage and Gender Differences between the Effects
Cardiovascular & Hematological Disorders-Drug Targets The Role of the Stress-Related Anti-Inflammatory Hormones ACTH and Cortisol in Atherosclerosis
Current Vascular Pharmacology Effects of Estrogens on Atherogenesis
Current Vascular Pharmacology Polyphenols: Biological Activities, Molecular Targets, and the Effect of Methylation
Current Molecular Pharmacology Nutritional and Therapeutic Potential of Spirulina
Current Pharmaceutical Biotechnology Emerging Therapeutic Approaches Multi-Targeting Receptor Tyrosine Kinases and G Protein-Coupled Receptors in Cardiovascular Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry Maternal Nutrition and Predisposition to Later Kidney Disease
Current Drug Targets Vascular Inflammation in Cardiovascular Disease: Is Immune System Protective or Bystander?
Current Pharmaceutical Design Cysteine Network (CYSTEINET) Dysregulation in Parkinson’s Disease: Role of N-acetylcysteine
Current Drug Metabolism Potential Prognostic, Diagnostic and Therapeutic Markers for In-stent Reocclusion in Advanced Age Patients After Coronary Stenting
Current Pharmaceutical Design